Advanced in Lung Nodules

Florian Guisier

CHU Rouen
Rouen, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Lung Nodules
CHU Rouen
Rouen, FR 
OverviewLocationsClinical Research

Overview

Florian Guisier practices in Rouen, France. Mr. Guisier is rated as an Advanced expert by MediFind in the treatment of Lung Nodules. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Nodules, Endoscopy, and Mastectomy.

His clinical research consists of co-authoring 101 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 9 articles in the study of Lung Nodules.

Gender
Male

Locations

CHU Rouen
Rouen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma
Randomized, Multicenter, Phase III Trial to Assess Conformal Post-operative Radiotherapy vs. Surveillance After Complete Resection of Stage II/III Thymoma
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Other
Study Phase: Not Applicable
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2025
Intervention Type: Other
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 24, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 3
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2025
Intervention Type: Drug, Other
Study Drug: Adjuvant Chemotherapy
Study Phase: Not Applicable
View 3 Less Clinical Trials

101 Total Publications

Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
Expression of Membrane Targets for Therapeutics in RET-Positive Non-Small Cell Lung Cancer.
Journal: JAMA oncology
Published: May 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guisier's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile